Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity

Journal of Medical Virology

Volumn 73, Issue 3, 2004, Pages 474-480

  Bousarghin, Latifa ^a   Touzé, Antoine ^a   Yvonnet, Bernard ^a   Coursaget, Pierre ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

Anti viral compounds; Cell entry; HPV; Neutralization; Pseudovirions; Virus like particles

Indexed keywords

CAPSID PROTEIN; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; GLYCOSAMINOGLYCAN; STRUCTURAL PROTEIN; SYNTHETIC PEPTIDE;

ANIMAL CELL; ARTICLE; CERCOPITHECIDAE; CONTROLLED STUDY; ELECTRON MICROSCOPY; GENE TRANSFER; NONHUMAN; PAPILLOMA VIRUS; POLYACRYLAMIDE GEL ELECTROPHORESIS; VIRION; VIRUS INFECTION; VIRUS PARTICLE; WART VIRUS;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRUS;

EID: 2542430315     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20114     Document Type: Article

References (47)

1. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. 1991. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J 60:1445-1456.
2. Bergsdorf C, Beyer C, Umansky V, Werr M, Sapp M. 2003. Highly efficient transport of carboxyfluorescein diacetate succinimidyl ester into COS7 cells using human papillomavirus-like particles. FEBS Lett 536:120-124.
3. Bestman-Smith JB, Piret J, Desormeaux A, Tremblay MJ, Omar RF, Bergeron MG. 2001. Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment. Antimicrob Agents Chemother 45:2229-2237.
4. Bonnez W, DaRin C, Borkhuis C, de Mesy Jensen K, Reichman RC, Rose RC. 1998. Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse. J Virol 72:5256-5261.
5. Bousarghin L, Touzé A, Combita AL, El Mehdaoui S, Sizaret P-Y, Bravo MM, Coursaget P. 2002. Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. J Clin Microbiol 40: 926-932.
6. Bousarghin L, Touzé A, Combita-Rojas AL, Sizaret P-Y, Coursaget P. 2003a. Positively charged sequences of human papillomavirus capsid proteins are sufficient to mediate gene transfer into target cells via heparan sulfate proteoglycan receptor. J Gen Virol 84:157-164.
7. Bousarghin L, Touzé A, Sizaret P-Y, Coursaget P. 2003b. Human papillomavirus type 16, 31, and 58 pseudovirions use different endocytosis pathways to enter cells. J Virol 77:3846-3850.
8. Cason J, Patel D, Naylor J, Lunney D, Shepherd PS, Best JM, McCance DJ. 1989. Identification of immunogenic regions of the major coat protein of human papillomavirus type 16 that contain type-restricted epitopes. J Gen Virol 70:2973-2987.
9. Christensen ND, Reed CA, Culp TD, Hermonat PL, Howett MK, Anderson RA, Zaneveld LJ. 2001. Papillomavirus microbicidal activities of high-molecular-weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate. Antimicrob Agents Chemother 45:3427-3432.
10. Combita AL, Touzé A, Bousarghin L, El Mehdaoui S, Sizaret P-Y, Muñoz N, Coursaget P. 2001. Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and required cell surface heparan sulfate. FEMS Microbiol Lett 204:183-188.
11. Combita AL, Touzé A, Bousarghin L, Christensen ND, Coursaget P. 2002. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomavirus. J Virol 76:6480-6486.
12. Datema R, Rabin L, Hincenbergs M, Moreno MB, Warren S, Linquist V, Rosenwirth B, Seifert J, McCune JM. 1996. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother 40:750-754.
13. Drobni P, Mistry N, McMillan N, Evander M. 2003. Carboxy-fluorescein diacetate, succinimidyl ester labeled papillomavirus virus-like particles fluoresce after internalization and interact with heparan sulfate for binding and entry. Virology 310:163-172.
14. El Mehdaoui S, Touzé A, Laurent S, Sizaret PY, Raschaert D, Coursaget P. 2000. Gene transfer using recombinant rabbit hemorrhagic disease virus capsids with genetically modified DNA encapsidation capacity by addition of packaging sequences from the L1 or L2 protein of human papillomavirus type 16. J Virol 74: 10332-10340.
15. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA. 1997. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 71:2449-2456.
16. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. 2001. Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75:1565-1570.
17. Hermonat PL, Daniel RW, Shah KS. 1992. The spermicide nonoxynol-9 does not inactivate papillomavirus. Sex Transm Dis 19:203-205.
18. Howett MK, Christensen ND, Kreider JW. 1997. Tissue xenografts as a model system for study of the pathogenesis of papillomaviruses. Clin Dermatol 15:229-236.
19. Howett MK, Neely EB, Christensen ND, Wigdahl B, Krebs FC, Malamud D, Patrick SD, Pickel MD, Welsh PA, Reed CA, Ward MG, Budgeon LR, Kreider JW. 1999. A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrob Agents Chemother 43:314-421.
20. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, Jansen KU, Keller PM. 1999. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274:5810-5822.
21. Judson FN, Ehret JM, Bodin GF, Levin MJ, Rietmeijer CA. 1989. In vitro evaluations of condoms with and without nonoxynol 9 as physical and chemical barriers against Chlamydia trachomatis, herpes simplex virus type 2, and human immunodeficiency virus. Sex Transm Dis 16:51-56.
22. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. 1998. In vitro construction of pseudovirions of human papillomavirus type 16: Incorporation of plasmid DNA into reassembled L1/L2 capsids. J Virol 72:10298-10300.
23. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR, Schiller JT. 1993. Efficient self assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67:6929-6936.
24. Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, Ruminjo I, Sajabi R, Kimata J, Fleming TR, Anzala A, Holton D, Plummer F. 1992. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 268:477-482.
25. Le Cann P, Coursaget P, Iochmann S, Touzé A. 1994. Self-assembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cells. FEMS Microbiol Lett 117:269-274.
26. McMillan NA, Payne E, Frazer IH, Evander M. 1999. Expression of the alpha6 integrin confers papillomavirus binding upon receptor-negative B-cells. Virology 261:271-279.
27. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527.
28. Pawellek A, Hewlett G, Kreuter J, Rubsamen-Waigmann H, Weber O. 2001. Xenograft model for identifying chemotherapeutic agents against papillomavirus. Antimicrob Agents Chemother 45:1014-1021.
29. Pisani P, Parkin DM, Bray F, Ferlay J. 1999. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18-29.
30. Rapp F, Wrzos H. 1985. Synergistic effect of human leukocyte interferon and nonoxynol-9 against herpes simplex virus type 2. Antimicrob Agents Chemother 28:449-451.
31. Richardson BA, Lavreys L, Martin HL, Jr., Stevens CE, Ngugi E, Mandaliya K, Bwayo J, Ndinya-Achola J, Kreiss JK. 2001. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: A randomized clinical trial. Sex Transm Dis 28:394-400.
32. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL. 1998. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 339: 504-510.
33. Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, Schiller JT. 1996. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 70:5875-5883.
34. Roden RB, Day PM, Bronzo BK, Yutzy WH IV, Yang Y, Lowy DR, Schiller JT. 2001. Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection. J Virol 75: 10493-10497.
35. Sadeyen JR, Tourne S, Shkreli M, Sizaret PY, Coursaget P. 2003. Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduced their immunogenicity and delineates a conformational neutralizing epitope. Virology 309:32-40.
36. Schiller JT, Roden RBS. 1996. Papillomavirus-like particles: Basic and applied studies. In: Lacey C, editor. Papillomavirus reviews: Current research on papillomaviruses. Leeds, UK: Leeds Medical Information. pp 101-112.
37. Silberstein E, Dveksler G, Kaplan GG. 2001. Neutralization of hepatitis A virus (HAV) by an immunoadhesin containing the cysteine-rich region of HAV cellular receptor-1. J Virol 75:717-725.
38. Touzé A, Coursaget P. 1998a. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 26:1317-1324.
39. Touzé A, El Mehdaoui S, Sizaret PY, Mougin C, Muñoz N, Coursaget P. 1998b. The L1 major capsid protein of human papillomavirus type 16 variants affects the yield of virus-like particle produced in an insect cells expression system. J Clin Microbiol 36:2046-2051.
40. Touzé A, Enogat N, Buisson Y, Coursaget P. 1999. Baculovirus expression of chimeric hepatitis B core particles with hepatitis E epitopes, and their use in a hepatitis E immunoassay. J Clin Microbiol 37:438-441.
41. Touzé A, Mahé D, El Mehdaoui S, Combita AL, Bousarghin L, Coursaget P. 2000. The 9 C-terminal amino acids of the major capsid protein of human papillomavirus type 16 are essential for DNA binding and gene transfer capacity. FEMS Microbiol Lett 189:121-127.
42. Trus BL, Roden RB, Greenstone HL, Vrhel M, Schiller JT, Booy FP. 1997. Novel structural features of bovine papillomayirus capsid revealed by a three-dimensional reconstruction to 9 Å resolution. Nat Struct Biol 4:413-420.
43. Unckell F, Streeck RE, Sapp M. 1997. Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol 71: 2934-2939.
44. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
45. Ward RL, Ashley CS. 1979. pH modification of the effects of detergents on the stability of enteric viruses. Appl Environ Microbiol 38: 314-322.
46. Weir SS, Roddy RE, Zekeng L, Feldblum PJ. 1995. Nonoxynol-9 use, genital ulcers, and HIV infection in a cohort of sex workers. Genitourin Med 71:78-81.
47. Weston SA, Parish CR. 1990. New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J Immunol Methods 133:87-97.